Wyeth's Phenergan Contraindicated In Patients Under Two Years Of Age
This article was originally published in The Pink Sheet Daily
Executive Summary
Postmarketing adverse event reporting finds cases of fatal respiratory depression, revised labeling says. Wyeth informs physicians of the labeling change in a "Dear Doctor" letter.
You may also be interested in...
FDA Issues Second Promethazine HCI Safety Alert
The agency said it has received reports of seven deaths and 22 cases of respiratory depression in children under the age of two.
NME Slowdown Shows Market Pressure On Me-Toos, Not FDA Caution – Lutter
DURHAM, N.C. - The decline in FDA's tally of new molecular entity approvals stems from fewer approvals of non-innovative products in recent years, while approvals of truly innovative products has largely held steady, according to FDA Deputy Commissioner for Policy, Planning and Preparedness Randall Lutter